StreetInsider.com News Articles

Form 4 SCYNEXIS INC For: Sep 09 Filed by: Subramanian Sanjay

Fri, 11 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260911/27052812.html

Form 3 SCYNEXIS INC For: Sep 09 Filed by: Subramanian Sanjay

Fri, 11 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260911/27052789.html

Form 8-K SCYNEXIS INC For: Sep 09

Thu, 10 Sep 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260910/27045535.html

Scynexis names Sanjay Subramanian as new CFO

Thu, 10 Sep 2026 08:01:02 -0400

Scynexis, Inc. (NASDAQ: SCYX) appointed Sanjay Subramanian as Chief Financial Officer, effective September 9, 2026, according to a company statement. The appointment follows the retirement of Ivor Macleod, who held the CFO role for nearly four years. Macleod will remain with the company through October 9, 2026 to assist with the transition.

Subramanian brings more than 20 years of experience in finance, capital markets, business development and operational leadership across the biotechnology, pharmaceutical and healthcare sectors. He most recently served as CFO and Head of Business Development at Inozyme Pharma, where he led the company's acquisition by BioMarin Pharmaceutical. He previously

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

Thu, 10 Sep 2026 08:00:00 -0400

JERSEY CITY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Sanjay Subramanian, MBA, as Chief Financial Officer, effective September 9, 2026. The Company also announced the retirement of Ivor Macleod from his role as Chief Financial Officer, effective September 9, 2026. Mr. Macleod will remain with the Company through October 9, 2026 to support a smooth transition.

"We are delighted to welcome Sanjay to SCYNEXIS and excited to add his

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

Thu, 10 Sep 2026 08:00:00 -0400

"We are delighted to welcome Sanjay to SCYNEXIS and excited to add his

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director’s employment with the Company, as a material inducement to the employee’s acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The award was granted

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

The award was granted

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

The award was granted

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

The award was granted

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26929154.html

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26929154.html

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26925867.html

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26925867.html

SCYNEXIS (SCYX) PT Raised to $33 at Guggenheim

Thu, 13 Aug 2026 06:47:48 -0400

(Updated - August 13, 2026 6:47 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on SCYNEXIS (NASDAQ: SCYX) to $33.00 (from $24.00) while maintaining a Buy rating.

The analyst commented: "We are increasing our price target on SCYX shares to $33 (from $24) and reiterating our Buy rating following multiple conversations with nephrologists that leave us more optimistic on both the mechanistic rationale and commercial opportunity for SCY-770 (formerly PXL-770) in autosomal dominant polycystic kidney disease (ADPKD). The transaction for SCY-770 with Poxel fundamentally reoriented SCYX from an antifungal-focused company to a rare renal disease company, with ADPKD the lead

SCYNEXIS (SCYX) PT Raised to $33 at Guggenheim

Thu, 13 Aug 2026 06:47:48 -0400

(Updated - August 13, 2026 6:47 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on SCYNEXIS (NASDAQ: SCYX) to $33.00 (from $24.00) while maintaining a Buy rating.

Form SCHEDULE 13G SCYNEXIS INC Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26911271.html

Form SCHEDULE 13G SCYNEXIS INC Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26911271.html

Scynexis (SCYX) Tops Q2 EPS by 114c

Mon, 10 Aug 2026 17:21:17 -0400

Scynexis (NASDAQ: SCYX) reported Q2 EPS of $0.63, $1.14 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $80.33 thousand.

For earnings history and earnings-related data on Scynexis (SCYX) click here.

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update